Biopharma/NIH 'PACT' Aims To Speed Cancer R&D
A group of drug companies are collaborating with the National Institutes of Health and others in the Partnership for Accelerating Cancer Therapies in an effort to fund precompetitive cancer research, whose data will be shared broadly, with the aim of bringing more new therapies to patients in less time.
You may also be interested in...
Richard Pazdur, who is moving from being the head of the FDA's Office of Hematology and Oncology Products (OHOP) to the agency's acting director of the newly created Oncology Center of Excellence, established under the White House's National Cancer Moonshot initiative, sat down with reporters on June 29 to explain his new role, but warned don't think he's just going to turn into some sort of a bureaucrat and to anticipate his presence to continue to very much be felt at OHOP.
Richard Pazdur has been tapped to run the FDA's new Oncology Center of Excellence, which is being created under the White House's National Cancer Moonshot initiative. That means Pazdur, who has been at the FDA since 1999, will be setting aside his duties, for the time being, running the Office of Hematology and Oncology Products – leaving that job in the interim to someone else.
Declaring the science is ready with immunotherapies, genomics and combination treatments, President Barack Obama and Vice President Joe Biden on Jan. 12 pledged to increase resources and breakdown silos in a new "moon shot" effort to fight cancer.